JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. IN PRACTICE
Abstract
Clinical Implications box: Baricitinib seems safe and effective in reducing the articular flares, controlling the systemic inflammation and lung disease progression of COPA patients. The drug dosage should be adjusted according to patient’s age and weight in order to prevent disease flares.
